<DOC>
	<DOCNO>NCT00218153</DOCNO>
	<brief_summary>Naltrexone Augmentation Nicotine Patch Therapy</brief_summary>
	<brief_title>Naltrexone Augmentation Nicotine Patch Therapy - 1</brief_title>
	<detailed_description>This double blind placebo control study design determine whether naltrexone use help reduce cigarette use crave cigarette . Eligible participant receive 21mg transdermal nicotine outpatient . In addition , participant receive one three dose naltrexone ( 25,50 100mg ) placebo brief counseling course six week follow-up appointment three , six , twelve month begin treatment .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Age 18 old 2 . Willingness ability give write consent 3 . Smoking 20 cigarette per day least 1 year 4 . At least one prior attempt stop smoking 5 . Baseline expire carbonmonoxide level least 10 ppm 6 . Weigh least 100 lb . 7 . English speak 8 . One person per household 1 . Pregnant nursing woman woman use reliable form birth control 2 . Unstable cardiac disease 3 . History dermatoses 4 . Current alcohol dependence 5 . Current use opiates 6 . A urine drug screen positive opiates 7 . Serious current neurologic , psychiatric medical illness 8 . Chronic pain condition necessitate opioid treatment 9 . Evidence significant hepatocellular injury evidence SGOT SGPT &gt; 3 x normal elevate bilirubin 10 . Current use smokeless tobacco , pipe , cigar , nicotine gum nicotine patch 11 . Patients require concomitant therapy psychotropic drug drug psychotropic component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>nicotine dependence</keyword>
</DOC>